Cerity Partners
IBRX icon

Cerity Partners’s ImmunityBio IBRX Stock Holding History

Cerity Partners’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Buy
26,009
+13,924
+115% +$105K ﹤0.01% 2983
2026
Q1 		$92.7K Buy
12,085
+1,098
+10% +$7.52K ﹤0.01% 3031
2025
Q4 		$21.8K Sell
10,987
-481
-4% -$1.09K ﹤0.01% 2844
2025
Q3 		$28.2K Buy
+11,468
New +$29.5K ﹤0.01% 2716
2023
Q2 		– Sell
-1,000
Closed -$5.07M – 1795
2023
Q1 		$5.07M Buy
+1,000
New +$3.11K 0.01% 497

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cerity Partners's IBRX Position: Q2 2026 in Review

Cerity Partners increased its ImmunityBio (IBRX) stake by 115% in Q2 2026, buying an estimated $105K and bringing the position to 26,009 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #2983.

Cerity Partners first reported a position in IBRX in Q1 2023 and has held it in 5 quarters since. The position peaked at $5.07M in Q1 2023. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Cerity Partners held 26,009 shares of ImmunityBio worth $228K as of Q2 2026.
  • Cerity Partners bought 13,924 ImmunityBio shares in Q2 2026, an estimated $105K.
  • ImmunityBio made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2983 holding.
  • Cerity Partners first reported a position in ImmunityBio in Q1 2023 and has held it in 5 quarters since.
  • Cerity Partners's ImmunityBio position peaked at $5.07M in Q1 2023.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.